IRVING, Texas, Aug 11, 2020 / PRNewswire / – Caris Life Sciences®, a leading innovator in molecular science focused on delivering the promise of precision medicine, today announced that it has entered into a strategic partnership with Elevation Oncology to improve patient recruitment practices for clinical trials genomic and tumor-free. Using Caris’ market-leading suite of molecular profiling offerings, Caris Pharmatech’s Just-In-Time (JIT) clinical trial solutions and the Caris Precision Oncology Alliance™ (POA), the companies will enhance traditional recruitment in Elevation Oncology’s Phase 2 CRESTONE trial through real-time, nationwide identification of eligible patients with neuregulin-positive fusion tumors- 1 (NRG1) and the use of flexible recruitment models for rapid initiation of study treatment.
“We are delighted to partner with Elevation Oncology and look forward to working with them to enhance their clinical trial recruitment efforts, with the ultimate goal of reducing the disease burden in NRG1 fusion positive patients in a range. of solid tumors, ”said David Spetzler, MS, Ph.D., MBA, President and Scientific Director. “The future of cancer treatment depends on clinical trials today, and we are excited to use our suite of industry-leading precision medicine technologies to address the challenges typically encountered in genomic trials.” and tumor agnostics. “
Under the terms of the agreement, Caris will help Elevation Oncology identify patients with advanced solid tumors who harbor NRG1 fusions to participate in Elevation Oncology’s CRESTONE trial. Eligible patients will be confirmed to participate in Elevation Oncology’s Phase 2 CRESTONE trial of seribantumab in adult patients with recurrent, locally advanced or metastatic solid tumors that harbor the NRG1 gene fusion.
Sarah Cannon Research Institute (Sarah Canon) has been selected as the first strategic site for CRESTONE and is currently open and recruiting patients. Eligible patients, including those in the Caris Pharmatech Oncology Trials Network and the Caris Precision Oncology Alliance Network, can potentially enroll in CRESTONE directly at their local oncology center, thereby minimizing travel and ensuring patient safety. in the face of ongoing restrictions due to COVID-19, and help deliver treatment options directly to patients who need them.
“Identifying oncogenic drivers, such as an NRG1 gene fusion, through advanced molecular testing is a critical first step in a patient’s treatment journey,” said Shawn leland, PharmD, RPh, Founder and Commercial Director of Elevation Oncology. “Based on the unique genomic signature of their tumor, doctors can identify the appropriate treatments or experimental trials for each patient. As an industry, we must stress the importance of collaborations between diagnostic providers and drug developers to ensure that the best outcomes for patients with rare and genomic cancers can be achieved. “
For more information on seribantumab and the CRESTONE study, please visit www.NRG1fusion.com.
About Caris Life Sciences
Caris Life Sciences® is a leading innovator in molecular science focused on delivering the promise of precision medicine through quality and innovation. The company’s advanced molecular profiling suite of offerings assesses DNA, RNA, and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more accurate and personalized treatment decisions. MI Exome™ whole exome sequencing with 22,000 DNA genes and MI Transcriptome™ Complete transcriptome sequencing with 22,000 RNA genes as well as analysis of cancer-related pathogens, bacteria, viruses and fungi performed on each patient provides the most comprehensive and clinically comprehensive DNA and RNA profiling relevant available in the market.
Caris is also advancing precision medicine with Caris MAI™ (Molecular Artificial Intelligence) which combines its innovative service offerings, Caris Molecular Intelligence® with its proprietary artificial intelligence analysis engine, DEAN™, to analyze the whole exome, the whole transcriptome and the whole cancer proteome. This information, coupled with mature clinical results on thousands of patients, provides unparalleled molecular solutions for patients, physicians, payers and biopharmaceutical organizations.
Caris Pharmatech is changing paradigm and streamlining the clinical trials process by helping biopharmaceutical companies access research-ready oncology sites for clinical trials. With more than 200 research sites within Caris Pharmatech’s JIT oncology network, biopharmaceutical companies can identify and recruit more patients faster. Caris Pharmatech’s just-in-time clinical trial solutions focus on rapid site activation and patient recruitment to streamline the drug development process. By implementing a just-in-time search (JIT) system, site activation and patient enrollment is achievable within 14 days for pre-registered locations with pre-qualified patients.
Based at Irving, Texas, Caris Life Sciences has offices in Phoenix, Denver, New York, and Basel, Switzerland. Caris provides services across the United States, Europe, Asia and other international markets. For more information, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
Caris Life Sciences media and company contact:
SOURCE Caris Life Sciences